<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28119761</article-id><article-id pub-id-type="pmc">5227155</article-id><article-id pub-id-type="doi">10.1155/2016/7173896</article-id><article-categories><subj-group subj-group-type="heading"><subject>Corrigendum</subject></subj-group></article-categories><title-group><article-title>Corrigendum to &#x0201c;IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety&#x0201d;</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Grube</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bongartz</surname><given-names>Udo</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Alt</surname><given-names>Felix</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Practice for General Medicine, Kurf&#x000fc;rstendamm 157/158, 10709 Berlin, Germany</aff><aff id="I2"><sup>2</sup>Analyze &#x00026; Realize GmbH, Wei&#x000df;enseer Weg 111, 10369 Berlin, Germany</aff><aff id="I3"><sup>3</sup>Analyze &#x00026; Realize GmbH, Waldseeweg 6, 13467 Berlin, Germany</aff><author-notes><corresp id="cor1">*Felix Alt: <email>falt@a-r.com</email></corresp></author-notes><pub-date pub-type="ppub"><year>2016</year></pub-date><pub-date pub-type="epub"><day>29</day><month>12</month><year>2016</year></pub-date><volume>2016</volume><elocation-id>7173896</elocation-id><history><date date-type="received"><day>18</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Barbara Grube et al.</copyright-statement><copyright-year>2016</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><related-article id="d35e122" related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.1155/2015/413075" vol="2015" elocation-id="413075"/></article-meta></front><body><p>In the article titled &#x0201c;IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety&#x0201d; [<xref rid="B1" ref-type="bibr">1</xref>], there was an error under Section 3.1.3: Hip Circumference, which should be corrected as follows.</p><p>
<italic>3.1.3. Hip Circumference</italic>. The mean hip circumference in the IQP-VV-102 group at baseline (V2) was 108.1&#x02009;cm (SD 6.7) while the placebo group was 106.5&#x02009;cm (SD 6.5) (<italic>p</italic> = 0.101).</p><p>In addition, the declaration statement in the Conflict of Interests section &#x0201c;The authors declare that there is no conflict of interests regarding the publication of this paper&#x0201d; should be replaced with the following declaration &#x0201c;InQpharm Europe Ltd. is the manufacturer of the investigational product and oversaw the trial and manuscript preparation as the sponsor.&#x0201d;</p></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grube</surname><given-names>B.</given-names></name><name><surname>Bongartz</surname><given-names>U.</given-names></name><name><surname>Alt</surname><given-names>F.</given-names></name></person-group><article-title>IQP-VV-102, a novel proprietary composition for weight reduction: a double-blind randomized clinical trial for evaluation of efficacy and safety</article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2015</year><volume>2015</volume><fpage>7</fpage><pub-id pub-id-type="publisher-id">413075</pub-id><pub-id pub-id-type="doi">10.1155/2015/413075</pub-id><pub-id pub-id-type="other">2-s2.0-84930648919</pub-id></element-citation></ref></ref-list></back></article>